Skip to content

A prospective, randomized controlled, multicenter clinical trial to evaluate the safety and efficacy of absorbable gradient membrane for periodontal soft tissue increment

A prospective, randomized controlled, multicenter clinical trial to evaluate the safety and efficacy of absorbable gradient membrane for periodontal soft tissue increment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034683
Enrollment
Unknown
Registered
2020-07-14
Start date
2020-09-15
Completion date
Unknown
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal soft tissue insufficient

Interventions

experimental group:Absorbale Gradient Membrane
control group:Free gingival graft

Sponsors

Affiliated Stomatological Hospital, Medical School of Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 70 years old, males or females; (2) Patients who need periodontal soft tissue increment treatment such as widened keratinized gingiva and deepened; vestibular sulcus, etc. (3) Those who agree to participate in the clinical trial and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) Patients who have undergone soft tissue incremental treatment at the treatment site; (2) Patients with infection at the treatment site; (3) Patients with complete loss of keratinized gingiva at the treatment site; (4) Patients who still need orthodontic tooth movement in the operation area during the trial; (5) Those who have not completed the basic periodontal treatment before surgery; (6) Patients undergoing bone augmentation at the same time at the treatment site; (7) Patients with severe liver and kidney abnormalities (any index of ALT/AST/Cr/BUN/UREA>1.5 times the upper limit of normal value); (8) Patients with poor blood glucose control (fasting blood glucose > 8.0 mmol/L); (9) Patients with severe hypertension who are not controlled to stable (systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 100 mmHg); (10) Patients with Severe abnormal blood coagulation function or platelets 10 cigarettes/ tobacco equivalents /chewing tobacco per day; (15) Patients with other contraindications for periodontal surgery; (16) Women who are pregnant/lactating or have a pregnancy plan within half a year; (17) Patients within 3 months or participating in clinical trials of other drugs/medical devices; (18) Other patients considered unsuitable for this clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Width increment of keratinized gingival ;

Secondary

MeasureTime frame
performance evaluation of devices;plaque index;probing depth,PD;( bleeding index, BI);Gingival recession;Width of keratinized gingival;VAS pain score;Operation time;soft tissue survival rate of Implant area;Wound healing;Surgery area satisfaction assessment;

Countries

China

Contacts

Public ContactYan Fuhua

Affiliated Stomatological Hospital, Medical School of Nanjing University

yanfh@nju.edu.cn+86 025-83620253

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026